Login / Signup

Topotecan in a Real-World Small-Cell Lung Cancer Cohort: Prognostic Biomarkers Improve Selection of Patients for Second-Line Treatment.

Laura LambrechtPaola ArnoldJuergen BehrPontus MertschAmanda TufmanDiego Kauffmann-Guerrero
Published in: Diagnostics (Basel, Switzerland) (2024)
The efficacy of topotecan in SCLC real-world patients is poor, indicating that many patients were treated without any benefit. Easy-to-obtain markers can predict response and treatment efficacy and should therefore be validated in larger cohorts to identify patients who are more likely to benefit from topotecan.
Keyphrases
  • end stage renal disease
  • small cell lung cancer
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • prognostic factors
  • combination therapy
  • smoking cessation